ABL Bio to Hold Online Corporate Presentation on the 30th

CEO Sanghoon Lee Communicates Directly with Investors

ABL Bio announced on the 24th that it will hold an analyst meeting and an online investor presentation on the 26th and 30th, respectively.

Following last year, ABL Bio plans to continue its shareholder-friendly approach by holding an investor presentation this year as well. In this presentation, the company will introduce the competitiveness and value of its clinical pipelines as well as strategies to secure continuous growth drivers. ABL Bio officials stated, "Since CEO Sanghoon Lee will directly communicate with shareholders and conduct a Q&A session, it will be an active platform for communication."

Sanghoon Lee, CEO of ABL Bio, said, "To keep our promise to investors to be a shareholder-friendly company, we planned both the analyst meeting and the online investor presentation again this year. Amid an unstable macro environment with concerns about economic recession, we hope this will be an opportunity for dialogue to empathize with shareholders' hardships and find breakthroughs together."

The analyst meeting will be held in Yeouido, and the online investor presentation will be broadcast live on the YouTube channel 'ABL Bio.' The broadcast will last about one hour, from noon to 1 p.m.

Meanwhile, ABL Bio is conducting more than 14 global clinical trials across the U.S., China, and Korea with over six pipelines including ABL001 (VEGFxDLL4) and ABL111 (Claudin18.2x4-1BB). Pipelines such as ABL103 (B7-H4x4-1BB) and ABL104 (EGFRx4-1BB) are also preparing to enter clinical trials.